KPL-716 Emerging Drug Insight and Market Forecast - 2032

“KPL-716 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about KPL-716 for Chronic Spontaneous Urticaria in seven major markets. A detailed picture of the KPL-716 for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the KPL-716 for Chronic Spontaneous Urticaria. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KPL-716 market forecast analysis for Chronic Spontaneous Urticaria in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Chronic Spontaneous Urticaria.

Drug Summary

Vixarelimab (KPL-716) is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes vixarelimab to be the only monoclonal antibody in development that targets both pathways simultaneously.

In September 2016, Kiniksa completed the acquisition of certain assets of Biogen under an asset purchase agreement or the Biogen Agreement. Under the Biogen Agreement, Kiniksa is obligated to use commercially reasonable efforts to develop and commercialize the acquired assets and made an upfront payment of USD 11.5 million and a technology transfer payment of USD 0.5 million to Biogen. Also, Kiniksa made a milestone payment of USD 4.0 million during the year ended December 31, 2017, associated with the achievement of a specified clinical milestone event. Kiniksa was also obligated to make future milestone payments for each antibody product that included the acquired assets, or an antibody product, of up to USD 325.0 million in the aggregate upon the achievement of specified milestones.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the KPL-716 description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria.
• Elaborated details on KPL-716 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KPL-716 research and development activities in Chronic Spontaneous Urticaria across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around KPL-716.
• The report contains forecasted sales of KPL-716 for Chronic Spontaneous Urticaria till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Chronic Spontaneous Urticaria.
• The report also features the SWOT analysis with analyst views for KPL-716 in Chronic Spontaneous Urticaria.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KPL-716 Analytical Perspective

In-depth KPL-716 Market Assessment

This report provides a detailed market assessment of KPL-716 for Chronic Spontaneous Urticaria in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

KPL-716 Clinical Assessment

The report provides the clinical trials information of KPL-716 for Chronic Spontaneous Urticaria covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KPL-716 dominance.
• Other emerging products for Chronic Spontaneous Urticaria are expected to give tough market competition to KPL-716 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KPL-716 in Chronic Spontaneous Urticaria.
• The in-depth analysis of the forecasted sales data of KPL-716 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KPL-716 in Chronic Spontaneous Urticaria.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of KPL-716?
• What is the clinical trial status of the study related to KPL-716 in Chronic Spontaneous Urticaria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KPL-716 development?
• What are the key designations that have been granted to KPL-716 for Chronic Spontaneous Urticaria?
• What is the forecasted market scenario of KPL-716 for Chronic Spontaneous Urticaria?
• What are the forecasted sales of KPL-716 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to KPL-716 for Chronic Spontaneous Urticaria?
• Which are the late-stage emerging therapies under development for the treatment of Chronic Spontaneous Urticaria?

This product will be delivered within 2 business days.